Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2003, p. 1672-1680, Vol. 47, No. 5
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.5.1672-1680.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Trends in Antimicrobial Susceptibilities among Enterobacteriaceae Isolated from Hospitalized Patients in the United States from 1998 to 2001
James A. Karlowsky,1* Mark E. Jones,2 Clyde Thornsberry,3 Ian R. Friedland,4 and Daniel F. Sahm1
Focus Technologies, Herndon, Virginia 20171,1
Focus Technologies, 1217 KP Hilversum, The Netherlands,2
Focus Technologies, Franklin, Tennessee 37064,3
Merck Research Laboratories, West Point, Pennsylvania 194864
Received 24 September 2002/
Returned for modification 20 December 2002/
Accepted 5 February 2003
Longitudinal surveillance of Enterobacteriaceae for antimicrobial susceptibility is important because species of this family are among the most significant and prevalent human pathogens. To estimate rates of in vitro antimicrobial susceptibility among hospitalized patients in the United States, data from The Surveillance Network were studied for 14 agents tested against 10 species of Enterobacteriaceae (n = 384,279) isolated from intensive-care-unit (ICU) patients and non-ICU inpatients from 1998 to 2001. Cumulative susceptibility (percent) data for all species of Enterobacteriaceae isolated from ICU patients and non-ICU inpatients, respectively, were ranked as follows: ampicillin-sulbactam (45.5 and 57.2) << ticarcillin-clavulanate (74.8 and 83.5) < trimethoprim-sulfamethoxazole (87.0 and 84.5)
cefotaxime (82.9 and 92.6) = ceftazidime (82.3 and 91.0) = ceftriaxone (86.5 and 93.9) = piperacillin-tazobactam (83.5 and 90.5) < levofloxacin (89.3 and 90.6) = ciprofloxacin (91.0 and 91.7) < gentamicin (91.8 and 94.3) < cefepime (95.0 and 97.9) < amikacin (98.5 and 99.2) < imipenem (100 and 100) = meropenem (100 and 100). Of those agents studied only susceptibilities to ciprofloxacin (94 to 89%) and levofloxacin (93 to 89%) decreased in a stepwise manner from 1998 to 2001. Decreased fluoroquinolone susceptibility was most pronounced for Escherichia coli, Proteus mirabilis, and Enterobacter cloacae. For all species of Enterobacteriaceae, trimethoprim-sulfamethoxazole resistance was more commonly observed in isolates with a single-drug resistance phenotype while gentamicin and fluoroquinolone resistances were more common in isolates resistant to at least one additional class of antimicrobial agent. Ongoing surveillance of Enterobacteriaceae will be particularly important to monitor changes in fluoroquinolone susceptibility, as well as changes in the prevalence of isolates resistant to multiple classes of antimicrobial agents.
* Corresponding author. Mailing address: Focus Technologies, 13665 Dulles Technology Dr., Suite 200, Herndon, VA 20171-4603. Phone: (703) 480-2575. Fax: (703) 480-2654. E-mail:
jkarlowsky{at}focusanswers.com.
Antimicrobial Agents and Chemotherapy, May 2003, p. 1672-1680, Vol. 47, No. 5
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.5.1672-1680.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Lockhart, S. R., Abramson, M. A., Beekmann, S. E., Gallagher, G., Riedel, S., Diekema, D. J., Quinn, J. P., Doern, G. V.
(2007). Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004. J. Clin. Microbiol.
45: 3352-3359
[Abstract]
[Full Text]
-
Walther-Rasmussen, J., Hoiby, N.
(2007). Class A carbapenemases. J Antimicrob Chemother
60: 470-482
[Abstract]
[Full Text]
-
Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M., Quale, J.
(2007). Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother
60: 78-82
[Abstract]
[Full Text]
-
Burgess, D. S., Frei, C. R.
(2005). Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother
56: 893-898
[Abstract]
[Full Text]
-
Lautenbach, E., Harris, A. D., Perencevich, E. N., Nachamkin, I., Tolomeo, P., Metlay, J. P.
(2005). Test Characteristics of Perirectal and Rectal Swab Compared to Stool Sample for Detection of Fluoroquinolone-Resistant Escherichia coli in the Gastrointestinal Tract. Antimicrob. Agents Chemother.
49: 798-800
[Abstract]
[Full Text]
-
Jacoby, G. A., Munoz-Price, L. S.
(2005). The New {beta}-Lactamases. NEJM
352: 380-391
[Full Text]
-
Woodford, N., Tierno, P. M. Jr., Young, K., Tysall, L., Palepou, M.-F. I., Ward, E., Painter, R. E., Suber, D. F., Shungu, D., Silver, L. L., Inglima, K., Kornblum, J., Livermore, D. M.
(2004). Outbreak of Klebsiella pneumoniae Producing a New Carbapenem- Hydrolyzing Class A {beta}-Lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother.
48: 4793-4799
[Abstract]
[Full Text]
-
Poirel, L., Heritier, C., Spicq, C., Nordmann, P.
(2004). In Vivo Acquisition of High-Level Resistance to Imipenem in Escherichia coli. J. Clin. Microbiol.
42: 3831-3833
[Abstract]
[Full Text]
-
Sarno, R., Ha, H., Weinsetel, N., Tolmasky, M. E.
(2003). Inhibition of Aminoglycoside 6'-N-Acetyltransferase Type Ib-Mediated Amikacin Resistance by Antisense Oligodeoxynucleotides. Antimicrob. Agents Chemother.
47: 3296-3304
[Abstract]
[Full Text]